Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Advaxis Inc

(NASDAQ: ADXS)
Add to Portfolio
+0.05 (+16.67%)
as of 16:00 EDT

Last 0.35
Change +0.05 (+16.67%)
Open 0.30
Prev. Close 0.30
Today's Range
0.29
0.36
52wk Range
0.26
14.55
Volume 16,968,365
Avg Volume 2,204,016
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
ADXS +16.67% -77.81% -96.96%
DJIA +0.13% +1.36% +3.35%
S&P 500 +0.03% +0.91% +3.45%

Key Statistics

Annual EPS -4.24
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 5,130
Weighted Alpha -95.41
Standard Deviation +2.97
Profit Margin N/A
Beta 3.21

Growth Rates

YTD -87.54%
1-Year -97.70%
3-Year -99.82%
5-Year -99.38%
10-Year -99.86%

Opinion

Sell Hold Buy

Recent Headlines

Dr. Robert Petit Follows His Passion to OS Therapies

BusinessWire via COMTEX - 02:46PM EDT
OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS), today announced the appointment of Robert Petit, Ph.D., as its Chief Medical (full story)
ADXS: 0.35 (+0.05)

Advaxis Reports Fiscal Third Quarter 2019 Financial

BusinessWire via COMTEX - Mon Sep 09, 08:00AM EDT
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results f(full story)
ADXS: 0.35 (+0.05)

Advaxis, Inc. Issues Letter to Shareholders

BusinessWire via COMTEX - Thu Aug 22, 08:00AM EDT
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A. Berlin, issue(full story)
ADXS: 0.35 (+0.05)

BriaCell Appoints Richard J. Berman to Board of

GlobeNewswire via COMTEX - Mon Aug 12, 06:30AM EDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed M(full story)
BCTXF: 0.0481 (-0.0054), ADXS: 0.35 (+0.05), IMRN: 2.84 (+0.01), CATS: 17.37 (+0.16), CYRX: 17.78 (-0.01), BCT.VN: 0.065 (unch), BIVI: 0.0750 (+0.0200)

Advaxis, Inc. Announces Closing of $17 Million Public

BusinessWire via COMTEX - Thu Jul 25, 11:30AM EDT
Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced un(full story)
ADXS: 0.35 (+0.05)